{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:06:06Z","timestamp":1788519966855,"version":"build-2803163510"},"reference-count":144,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Essential tremor (ET) is a common hyperkinetic movement disorder and causes significant disability. However, the response to the commonly used medications is often unsatisfactory. Hence, there is a requirement for improved treatment modalities involving novel therapeutic targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the literature on the recent clinical and preclinical studies regarding the treatment of ET, to identify and discuss the emerging therapeutic targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The authors conducted a literature search on PubMed and Scopus on March 25, 2025 using different search terms and included the relevant articles in the review. Ongoing clinical trials in ET were noted by searching\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Evidence collected from preclinical studies has led to clinical trials on several pharmacological agents such as T\u2010type calcium channel antagonists, GABA\n                      <jats:sub>A<\/jats:sub>\n                      receptor modulators, SK channel modulators, and agents targeting glutamatergic neurotransmission. However, some promising clinical trials had negative results, and the outcomes of the other phase 2 and 3 studies are still pending. Preclinical studies have identified other pharmacological targets that have yet to be replicated in clinical studies. Regarding deep brain stimulation and magnetic resonance\u2010guided focused ultrasound surgery, in addition to the thalamic ventralis intermedius nucleus, the posterior subthalamic area has also shown efficacy, possibly due to its proximity to the dentato\u2010rubro\u2010thalamic tract. Non\u2010invasive brain, spinal cord, and peripheral stimulation techniques are the other potential treatment modalities investigated in ET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>New therapeutic targets including pharmacological, surgical, and non\u2010invasive stimulation techniques have shown promise in ET. Translating preclinical research into useful treatment strategies requires further clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70147","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:26:06Z","timestamp":1748233566000},"page":"1722-1741","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current and Emerging Therapeutic Targets for Essential Tremor: A Critical Appraisal of Recent Preclinical and Clinical Studies"],"prefix":"10.1002","volume":"12","author":[{"given":"Adreesh","family":"Mukherjee","sequence":"first","affiliation":[{"name":"Department of Neurology North Bengal Medical College  Darjeeling India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-9137","authenticated-orcid":false,"given":"Sanjay","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke Medicine Amrita Institute of Medical Sciences  Faridabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.632"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27121"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000509"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1707928"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27700"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2019-136647"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02926.x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.05.008"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.05.012"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21282"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22418"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.7916\/D8FQ9WN0"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28584"},{"key":"e_1_2_12_15_1","unstructured":"Jazz Pharmaceuticals.Jazz Pharmaceuticals provides update on phase 2b trial of investigational suvecaltamide (JZP385) in essential tremor. News release;2024. June 20 2024. Accessed March 25 2025.https:\/\/www.prnewswire.com\/news\u2010releases\/jazz\u2010pharmaceuticals\u2010provides\u2010update\u2010on\u2010phase\u20102b\u2010trial\u2010of\u2010investigational\u2010suvecaltamide\u2010jzp385\u2010in\u2010essential\u2010tremor\u2010302177347.html."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28969"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","unstructured":"OlhayeO BelfortG RainesS SnyderT RavinaB.A phase 2 clinical trial evaluating the efficacy safety tolerability and pharmacokinetics of PRAX\u2010944 in adults with essential tremor [abstract];2022.https:\/\/www.mdsabstracts.org\/abstract\/a\u2010phase\u20102\u2010clinical\u2010trial\u2010evaluating\u2010the\u2010efficacy\u2010safety\u2010tolerability\u2010and\u2010pharmacokinetics\u2010of\u2010prax\u2010944\u2010in\u2010adults\u2010with\u2010essential\u2010tremor\/.","DOI":"10.1212\/WNL.98.18_supplement.1557"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205217"},{"key":"e_1_2_12_19_1","unstructured":"deCubaC SmitsL KremerP et al.An evaluation of NBI\u2010827104 for essential tremor: results from a randomized double\u2010blind placebo\u2010controlled dose\u2010escalation crossover study [abstract];2023.https:\/\/www.mdsabstracts.org\/abstract\/an\u2010evaluation\u2010of\u2010nbi\u2010827104\u2010for\u2010essential\u2010tremor\u2010results\u2010from\u2010a\u2010randomized\u2010double\u2010blind\u2010placebo\u2010controlled\u2010dose\u2010escalation\u2010crossover\u2010study\/."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.7916\/D8JW9X9K"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-020-01106-w"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020197"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01342-y"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.834"},{"key":"e_1_2_12_25_1","article-title":"GABA\u2010A receptor positive allosteric modulators: phase 2 proof of concept studies of Brexanolone injection and SAGE\u2010217 in essential tremor [abstract]","volume":"34","author":"Paskavitz J","year":"2019","journal-title":"Mov Disord"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29731"},{"key":"e_1_2_12_27_1","unstructured":"Sage Therapeutics and Biogen.Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE\u2010324 (BIIB124) for the Treatment of Essential Tremor. News release;2024. July 24 2024. Accessed March 25 2025.https:\/\/investors.biogen.com\/news-releases\/news-release-details\/sage-therapeutics-and-biogen-announce-topline-results-phase-2."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.05.015"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.08.014"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2015.01.078"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1538\/expanim.20-0025"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135881"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20676"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181ebd109"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12927"},{"key":"e_1_2_12_36_1","unstructured":"Efficacy Safety and Pharmacokinetics of ES\u2010481 in Adult Patients With Essential Tremors; ClinicalTrials.gov identifier: NCT05234762. Updated March 2 2023. Accessed March 25 2025.https:\/\/clinicaltrials.gov\/study\/NCT05234762."},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12692"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2019.12.045"},{"key":"e_1_2_12_39_1","unstructured":"CurtisM ElbleR KuoS et al.Phase 2a open\u2010label study to evaluate the safety tolerability and efficacy of CAD\u20101883 in essential tremor (Cadence\u20101) [abstract];2020.https:\/\/www.pascongress.org\/MDS-PAS-2019-Files\/20PAS-LBA-booklet_v2.pdf."},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-012-0121-1"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000101722.95137.19"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2018.03.016"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-020-03010-5"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31824687bf"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20940"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13581"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.06.015"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.21315\/mjms2019.26.4.4"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60518-4"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02602-z"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51735"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1413353"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002995107"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.7916\/D89S37MV"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.074120"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr301"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.796"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23625"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.760"},{"key":"e_1_2_12_60_1","unstructured":"Springer Nature.Drug Profile Brexanolone\u2014Sage Therapeutics. Adisinsight; February 27 2025. Accessed March 25 2025.https:\/\/adisinsight.springer.com\/drugs\/800039944."},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.7916\/D8TD9W2P"},{"key":"e_1_2_12_62_1","doi-asserted-by":"crossref","unstructured":"O'BrienT FosterE MillistL et al.Efficacy and safety of ES\u2010481 a novel TARP inhibitor in drug\u2010resistant epilepsy: a double\u2010blind randomized placebo controlled phase IIa trial [abstract];2024.https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000206132.","DOI":"10.1212\/WNL.0000000000206132"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.04.031"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2022.02.008"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2017.09.012"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12467"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1028360"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.06.019"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12120807"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002173420703"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2486065"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27821"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120190"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005956"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13729"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13878"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000522573"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.06.019"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2017.11.064"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12565"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvoice.2015.04.003"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489938"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29717"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102235"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/19714009211036689"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurom.2022.04.040"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2023.02.002"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102846"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.3171\/2024.3.FOCUS2425"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1159\/000493546"},{"key":"e_1_2_12_91_1","unstructured":"Academisch Medisch Centrum \u2010 Universiteit van Amsterdam.The STEREO\u2010DBS ET Study: 7\u2010Tesla MRI Brain Network Analysis for Deep Brain Stimulation in Essential Tremor (STEREO\u2010ET);ClinicalTrials.govidentifier: NCT05909839. Updated July 6 2023. Accessed March 25 2025.https:\/\/clinicaltrials.gov\/study\/NCT05909839."},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-022-01185-8"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.628"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/ner.13234"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/ner.13301"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28513"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay7680"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2021.09.002"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120193"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.3171\/2017.11.FOCUS17628"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27401"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29801"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.09.013"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14005"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1227\/ons.0000000000001457"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1227\/neuprac.0000000000000101"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00705-7"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106040"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328459"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13882"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26925"},{"key":"e_1_2_12_112_1","unstructured":"Iorio\u2010MorinC Universit\u00e9 de Sherbrook.Bilateral Essential Tremor Treatment With Gamma Knife (BEST\u2010GK); ClinicalTrials.gov identifier: NCT04748640. Updated November 17 2021. Accessed March 25 2025.https:\/\/clinicaltrials.gov\/study\/NCT04748640."},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29790"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2012.04.009"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2926"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2023.0348"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2019.10.003"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.03.019"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2016.08.003"},{"issue":"2","key":"e_1_2_12_120_1","article-title":"Transcranial static magnetic field stimulation of the primary motor cortex in essential tremor [abstract]","volume":"37","author":"Urso D","year":"2022","journal-title":"Mov Disord"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20581-7"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01372-6"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2014.02.001"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000070"},{"key":"e_1_2_12_125_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1117188"},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2018.08.014"},{"key":"e_1_2_12_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2024.05.003"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1088\/1741-2552\/ad27ef"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29966"},{"key":"e_1_2_12_130_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.685"},{"key":"e_1_2_12_131_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.715"},{"key":"e_1_2_12_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/ner.12930"},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.59"},{"key":"e_1_2_12_134_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.798"},{"key":"e_1_2_12_135_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.565"},{"key":"e_1_2_12_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96660-6"},{"key":"e_1_2_12_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106086"},{"key":"e_1_2_12_138_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.991"},{"key":"e_1_2_12_139_1","doi-asserted-by":"publisher","DOI":"10.3390\/bios11040099"},{"key":"e_1_2_12_140_1","doi-asserted-by":"publisher","DOI":"10.7916\/tohm.v0.688"},{"key":"e_1_2_12_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30102"},{"key":"e_1_2_12_142_1","unstructured":"Hospices Civils de Lyon.Nonlinear Absorber in Essential Tremor Treatment (TREM\u2010AB);ClinicalTrials.govidentifier: NCT06397391. Updated January 15 2025. Accessed March 25 2025.https:\/\/clinicaltrials.gov\/study\/NCT06397391."},{"key":"e_1_2_12_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52988-8"},{"key":"e_1_2_12_144_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100552"},{"key":"e_1_2_12_145_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.930"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:03:49Z","timestamp":1763474629000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":144,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/mdc3.70147"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70147","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"2024-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}